Gilead Sciences (NASDAQ:GILD) Announces Quarterly Earnings Results

Posted by Stanley Muller on Aug 5th, 2026

Gilead Sciences logo Gilead Sciences (NASDAQ:GILD – Get Free Report) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.26) by $0.51, Zacks reports. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.01 earnings per share.

Gilead Sciences Trading Up 0.5%

Gilead Sciences stock opened at $135.94 on Wednesday. The stock has a market cap of $168.78 billion, a PE ratio of 18.52 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock has a 50-day moving average price of $129.58 and a 200 day moving average price of $136.11. Gilead Sciences has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Analysts Set New Price Targets

GILD has been the subject of a number of recent research reports. Royal Bank Of Canada decreased their price target on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. Morgan Stanley dropped their price target on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Citigroup lifted their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Finally, Daiwa Securities Group lowered their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $157.93.

Get Our Latest Stock Analysis on GILD

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 82,000 shares of company stock worth $10,641,790. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vermillion & White Wealth Management Group LLC raised its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $26,000. Swiss RE Ltd. bought a new stake in Gilead Sciences in the 4th quarter valued at about $31,000. Mcguire Capital Advisors Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $43,000. Finally, Acumen Wealth Advisors LLC bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, up 10.6% year over year and above the $7.4 billion consensus estimate. Its $6.75 per-share loss was narrower than analysts’ expected loss of approximately $7.07–$7.26. Gilead Q2 Results
Positive Sentiment: HIV remained the primary growth driver. Product sales excluding Veklury rose 10% to $7.6 billion, while management raised its 2026 HIV growth outlook to 9%–10%. PrEP sales, including the newer Yeztugo product, reportedly doubled to about $1 billion, supporting the possibility of a durable HIV growth engine. Gilead Raises HIV Outlook
Positive Sentiment: Cantor Fitzgerald reaffirmed its “overweight” rating with a $155 price target, while Needham reaffirmed its “buy” rating and set a $170 target. The recommendations imply meaningful upside from recent trading levels. Analyst Ratings via Benzinga
Positive Sentiment: The California Supreme Court ruled in Gilead’s favor in a case involving whether drugmakers must develop potentially safer alternatives to existing safe medicines, reducing a notable product-liability risk. California Supreme Court Ruling
Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, or $3.28 annualized, yielding approximately 2.4%. The dividend is payable September 29 to shareholders of record September 15.
Negative Sentiment: Veklury sales fell 81% year over year, prompting Gilead to lower its full-year outlook for the COVID-19 treatment. The company also swung from $2.01 of earnings per share a year earlier to a quarterly loss as acquisition-related costs and R&D spending increased. Veklury and R&D Costs
Negative Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $1.95 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, and he retained more than 592,000 shares, limiting its significance as a bearish signal.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.